| abstract |
The present invention is directed to (i) a renin inhibitor, or a pharmaceutically acceptable salt thereof, for the prevention, delay and / or treatment of a disease or condition mediated by angiotensin II and / or NEP activity ( ii) neutral endopeptidase (NEP) inhibitors, or pharmaceutically acceptable salts thereof, and optionally (a) diuretics, or pharmaceutically acceptable salts thereof, and (b) angiotensin II receptor A combination comprising at least one therapeutic agent selected from the group consisting of a body blocker (ARB), or a pharmaceutically acceptable salt thereof (the method comprising: Including administering a therapeutically effective amount to a warm-blooded animal in need thereof). |